LACTOLOGY FOUNDATION

Drugs in ATC class A03CC are fixed combinations of antispasmodics with psycholeptics, used mainly for functional gastrointestinal disorders with a significant central anxiety/sedative component, and they require particular caution in lactating patients due to additive anticholinergic and CNS‑depressant effects.medpedia.framar+3

ATC Group A03CC Overview

A03CC (“Other antispasmodics in combination with psycholeptics”) belongs to A03C (antispasmodics in combination with psycholeptics) within the A03 group “Drugs for functional gastrointestinal disorders.”atcddd.fhi+2
These medicines pair smooth‑muscle relaxants with centrally acting psycholeptics (most commonly benzodiazepines) to address both visceral spasm and associated anxiety or tension.prescriberpoint+2

The group is defined by its gastrointestinal indication rather than by a single active ingredient, and classification at the fifth level is based mainly on the antispasmodic component.atcddd.fhi+1

Representative Active Substances

A prototypical A03CC product combines clidinium bromide (anticholinergic antispasmodic) with chlordiazepoxide (benzodiazepine anxiolytic/sedative).medlineplus+3
Clidinium reduces gastrointestinal motility and gastric acid secretion via peripheral muscarinic blockade, while chlordiazepoxide enhances GABAergic neurotransmission in the CNS, providing anxiolytic, sedative, and muscle‑relaxant effects.pdf.hres+3

Fixed combinations of belladonna‑type or other antispasmodics with psycholeptics that are not classified in A03CB (belladonna and derivatives with psycholeptics) may also be placed in A03CC, depending on their exact composition.wikipedia+2

Mechanism of Action

The antispasmodic component (e.g., clidinium) acts as a competitive antagonist at muscarinic acetylcholine receptors in smooth muscle of the gastrointestinal tract, leading to decreased motility, reduced spasms, and diminished secretory activity.mayoclinic+3
This peripheral action alleviates cramp‑like abdominal pain, bowel urgency, and hypermotility associated with functional gastrointestinal disorders.medpedia.framar+1

The psycholeptic component (e.g., chlordiazepoxide) potentiates the inhibitory effect of GABA at GABAA_AA​ receptors, producing a spectrum of CNS depression from mild sedation to pronounced anxiolysis.prescriberpoint+2
Clinically, this leads to reduced emotional tension, improved pain tolerance, and attenuation of the brain–gut axis hyperreactivity often seen in irritable bowel syndrome and stress‑related GI conditions.mayoclinic+1

Therapeutic Indications

A03CC combinations are indicated as adjunctive therapy in:medpedia.framar+2

• Irritable bowel syndrome and other functional bowel disorders with spasm and pain (e.g. spastic colon, mucous colitis).prescriberpoint+2
• Peptic ulcer disease and dyspeptic complaints, when a spastic and anxiety component is present.mayoclinic+1
• Acute enterocolitis and other GI conditions characterized by painful smooth‑muscle spasm and marked psychogenic overlay.medpedia.framar+2

These combinations are generally reserved for patients in whom non‑sedating antispasmodics and non‑pharmacological measures are insufficient to control symptoms and anxiety.prescriberpoint+1

Posology and Administration (General)

Products in this group are usually administered orally in capsule or tablet form, in divided doses throughout the day, often before meals and at bedtime.mayoclinic+1
Typical adult regimens for clidinium/chlordiazepoxide combinations involve 1–2 capsules three or four times daily, titrated according to symptom control and tolerability, while older adults generally require lower total daily doses.prescriberpoint+1

Treatment duration should be as short as possible, reflecting benzodiazepine‑related risks such as dependence, tolerance, and withdrawal; periodic re‑evaluation of the need for therapy is essential.pdf.hres+2

Adverse Effects

Adverse reactions reflect both the anticholinergic and benzodiazepine components.medlineplus+3

Typical anticholinergic‑related effects include:medlineplus+2

• Dry mouth, decreased sweating, constipation, and decreased peristalsis (with risk of paralytic ileus in predisposed patients).pdf.hres+2
• Blurred vision, mydriasis, and increased intraocular pressure, posing particular risk in narrow‑angle glaucoma.medlineplus+2
• Urinary hesitancy or retention, especially in men with prostatic hypertrophy or bladder neck obstruction.pdf.hres+1

Benzodiazepine‑related effects include:medlineplus+2

• Drowsiness, fatigue, cognitive slowing, ataxia, and coordination problems, increasing the risk of falls and accidents.pdf.hres+2
• Paradoxical reactions such as agitation, excitement, irritability, or insomnia, especially in older adults.medlineplus+1
• Respiratory depression, profound sedation, and, in severe cases, coma, particularly when co‑administered with other CNS depressants (opioids, alcohol, sedative‑hypnotics).mayoclinic+2

Less frequent but clinically significant reactions reported with representative products include jaundice, hematologic abnormalities (e.g. leukopenia, agranulocytosis), and skin rash or urticaria.pdf.hres+1

Contraindications and Precautions

Class‑typical contraindications arise mainly from the anticholinergic and benzodiazepine components.mayoclinic+2

Absolute or major contraindications:medlineplus+2

• Narrow‑angle glaucoma or significantly elevated intraocular pressure.pdf.hres+2
• Prostatic hypertrophy and bladder neck obstruction with risk of urinary retention.medlineplus+1
• Known hypersensitivity to the active substances (e.g. clidinium, chlordiazepoxide) or excipients.pdf.hres+1

Important precautions:mayoclinic+2

• Use with extreme caution in older adults and debilitated patients due to heightened sensitivity to anticholinergic and CNS‑depressant effects.mayoclinic+2
• Dose adjustment or avoidance in severe hepatic or renal impairment, where benzodiazepine metabolism and elimination may be reduced.medlineplus+1
• Avoidance of concomitant alcohol and cautious use with opioids, other benzodiazepines, or sedative drugs, given the risk of additive respiratory and CNS depression.prescriberpoint+2
• Gradual tapering after prolonged treatment to minimize benzodiazepine withdrawal symptoms.pdf.hres+1

Drug Interactions

Clinically relevant interactions involve additive pharmacodynamic effects and altered pharmacokinetics of benzodiazepines.prescriberpoint+3
Concurrent use with opioids, other benzodiazepines, sedative antidepressants, antipsychotics, or alcohol can significantly increase the risk of sedation, respiratory depression, and psychomotor impairment.prescriberpoint+2

Anticholinergic burden may be additive when A03CC products are combined with other anticholinergic agents (e.g. tricyclic antidepressants, certain antihistamines, antiparkinsonian drugs), enhancing risks of confusion, constipation, urinary retention, and hyperthermia.mayoclinic+2
Enzyme‑modifying drugs that affect benzodiazepine metabolism (strong CYP3A or CYP2C modulators) may alter chlordiazepoxide exposure, although the exact clinical magnitude depends on the specific combination.prescriberpoint+1

Use in Lactation: Toxicological–Lactological Assessment

From a lactation‑safety perspective, A03CC combinations pose concern due to both drug classes.medlineplus+2

Transfer into Breast Milk and Infant Exposure

Chlordiazepoxide and its active metabolites can cross into breast milk; benzodiazepines in general have variable but often measurable milk levels, correlating with risks of infant sedation and accumulation during chronic maternal use.pdf.hres+1
Clidinium and similar strongly anticholinergic antispasmodics may also reach the infant, although quantitative milk data are limited, and the primary concern is pharmacodynamic rather than dose‑related toxicity.medlineplus+1

Documented and Theoretical Risks for the Breastfed Infant

Potential infant effects linked to maternal use of chlordiazepoxide‑containing combinations include excessive sleepiness, hypotonia (“floppiness”), poor suck, feeding difficulties, and, in more severe cases, respiratory depression.pdf.hres+1
With prolonged maternal exposure or higher doses, benzodiazepine accumulation in the infant may theoretically predispose to withdrawal phenomena if breast‑feeding is interrupted abruptly.pdf.hres

Anticholinergic exposure may contribute to constipation, decreased gastrointestinal motility, urinary retention, and potential disturbances in visual accommodation in the infant, though robust clinical data are sparse.medlineplus+1
Given the limited safety data and the availability of non‑sedating alternatives, these combinations are generally not preferred for breastfeeding women, particularly when treating benign functional disorders.mayoclinic+2

Effect on Lactation and Breast Milk Production

Clidinium‑containing medications have been noted to potentially inhibit lactation, presumably through anticholinergic interference with hormonal and reflex regulation of milk production.medlineplus+1
In addition, the sedative/anxiolytic effect of benzodiazepines may secondarily affect maternal–infant interaction, night feeds, and adherence to on‑demand breastfeeding patterns, indirectly reducing milk supply.mayoclinic+1

Clinical Recommendations for Breastfeeding

Product‑level information for clidinium/chlordiazepoxide combinations advises that breastfeeding women should generally avoid these medicines or use them only if the potential maternal benefit clearly outweighs the possible risks to the infant.pdf.hres+1
If exceptional short‑term use in a lactating woman is deemed necessary, close monitoring of the infant for signs of excessive sedation, poor feeding, weight gain failure, constipation, or respiratory compromise is mandatory, and a lower effective maternal dose for the shortest possible duration is advisable.mayoclinic+2

From a toxicological‑lactological standpoint, safer alternatives should be prioritized: non‑sedating antispasmodics (e.g. pure antimuscarinics or other GI‑targeted agents with better lactation safety profiles) and non‑benzodiazepine approaches for anxiety (psychological therapies, compatible pharmacotherapy) should be considered before resorting to A03CC combinations in breastfeeding women.atccode+2

Summary Toxicological–Lactological Appraisal

The risk profile in lactation is driven by:mayoclinic+2

• Maternal benzodiazepine exposure (sedation, dependence potential, milk transfer).
• Strong anticholinergic effects influencing both infant physiology and maternal lactogenesis.

Overall, A03CC medicines are best categorized as “not preferred in breastfeeding; use only if no safer alternatives exist, at the lowest effective dose, for short courses, with strict infant monitoring.”medlineplus+2
Chronic therapy in breastfeeding women should generally be avoided, and, when ongoing treatment with such combinations is unavoidable, individualized risk–benefit evaluation and possible partial or complete substitution of breastfeeding may be required.pdf.hres+2